Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 13/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481641 | 1.00 | GRIN1 (0.44) | GRIN1GRIN2BACVR1FYNPRKCQ | |
| SCHEMBL481699 | 1.00 | GRIN1 (0.44) | GRIN1GRIN2BACVR1FYNPRKCQ | |
| SCHEMBL2507320 | 0.89 | ACVR1 (0.45) | GRIN1GRIN2BACVR1 | |
| SCHEMBL481704 | 0.80 | FYN (0.55) | ACVR1FYNUSP1 | |
| SCHEMBL481377 | 0.80 | USP1 (0.46) | ACVR1FYNUSP1 | |
| SCHEMBL481376 | 0.80 | USP1 (0.46) | ACVR1FYNUSP1 | |
| SCHEMBL481660 | 0.80 | USP1 (0.46) | ACVR1FYNUSP1 | |
| SCHEMBL481543 | 0.80 | FYN (0.55) | ACVR1FYNUSP1 | |
| SCHEMBL481545 | 0.80 | FYN (0.55) | ACVR1FYNUSP1 | |
| SCHEMBL481616 | 0.76 | USP1 (0.43) | ACVR1FYNUSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372976-B2 | Methods of treatment comprising the administration of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | GRIN1 2710/4885GRIN2B 2853/4885ACVR1 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.